Connect to MCP

Claude DesktopClaude Code (CLI)ChatGPTCursorVS Code

HighTide Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for HighTide Therapeutics.

Start Free TrialSee companies similar to HighTide Therapeutics

HighTide Therapeutics Overview

About HighTide Therapeutics

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Founded

2018

HQ

China

Employees

70

Financials (FY)

Revenue: -
EBITDA: ($33M)

EV

$173M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

HighTide Therapeutics Financials

HighTide Therapeutics reported last fiscal year revenue of - and negative EBITDA of ($33M).

In the same fiscal year, HighTide Therapeutics generated ($33M) in EBITDA losses and had net loss of ($34M).

HighTide Therapeutics P&L

In the most recent fiscal year, HighTide Therapeutics reported revenue of - and EBITDA of ($33M).

HighTide Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for HighTide Therapeutics
Last FY202320242025202620272028
EBITDA($33M)($139M)($55M)($33M)
Net Profit($34M)($139M)($57M)($34M)

Financial data powered by Morningstar, Inc.

HighTide Therapeutics Stock Performance

HighTide Therapeutics has current market cap of $228M, and enterprise value of $173M.

HighTide Therapeutics' stock price is $0.45.

HighTide Therapeutics has an EPS (earnings per share) of $-0.07.

See more trading valuation data for HighTide Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$173M$228M0.0%---$-0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

HighTide Therapeutics Valuation Multiples

HighTide Therapeutics trades at (5.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for HighTide Therapeutics

HighTide Therapeutics Financial Valuation Multiples

As of August 14, 2026, HighTide Therapeutics has market cap of $228M and EV of $173M.

HighTide Therapeutics has a P/E ratio of (6.6x).

Last FY202320242025202620272028
EV/EBITDA(5.2x)(1.2x)(3.1x)(5.2x)
EV/EBIT(5.4x)(2.7x)(2.9x)(5.4x)
P/E(6.6x)(1.6x)(4.0x)(6.6x)
EV/FCF(7.0x)(3.2x)(3.8x)(7.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified HighTide Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

HighTide Therapeutics Margins & Growth Rates

See estimated margins and future growth rates for HighTide Therapeutics

HighTide Therapeutics Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth(60%)(40%)
EBIT Growth(7%)(47%)
Net Profit Growth(59%)(39%)
FCF Growth(16%)(45%)

Data powered by FactSet, Inc. and Morningstar, Inc.

HighTide Therapeutics Operational KPIs

HighTide Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for HighTide Therapeutics
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.5M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

HighTide Therapeutics Competitors

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E

This data is available for Pro users. Sign up to see all HighTide Therapeutics competitors and their valuation data.

Start Free Trial

HighTide Therapeutics VC Funding History

Before going public, HighTide Therapeutics raised $167M in total equity funding, across 2 rounds.

HighTide Therapeutics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-23Series CChina Development Bank Capital; Yuthai Fund; Guangzhou Yuexiu Industrial Investment Fund$107M-HighTide Therapeutics Inc. is a global clinical-stage biopharmaceutical company focused on developing novel multifunctional therapies for metabolic and digestive diseases, with operations in the US, China, Hong Kong, and Australia. Its lead candidate, HTD1801 (berberine ursodeoxycholate), is a gut-liver anti-inflammatory metabolic modulator targeting conditions like NASH, PSC, T2DM with metabolic comorbidities, and dyslipidemia. HTD1801 has received FDA Fast Track and Orphan Drug designations for NASH and PSC, and inclusion in China's National Major New Drug Innovation Program. The company has conducted 13 global clinical trials across multiple countries and was ranked among China's top 30 small-molecule drug innovators for three years running as of 2023. In January 2023, HighTide announced the closing of a $107 million Series C/C+ financing round led by the TCM Healthcare Fund of Guangdong (managed by China Development Bank Capital), with participation from Guangzhou Yuexiu Industrial Investment Fund (Yuexiu Fund) and Yuthai Fund. This followed a $60 million Series B+ round in late 2020. Proceeds are allocated to advance global clinical programs, including mid- to late-stage trials for HTD1801 (e.g., Phase IIb global multi-center and Phase III in China), commercialization, and business development. Patient enrollment for Phase III trials was set to complete in 2024, with data readout planned for 2025. HighTide listed on the Hong Kong Stock Exchange Main Board in 2023, marking its first full financial year as a public company. The 2023 annual report details R&D expenses rising 70.6% to RMB311.6 million from RMB182.7 million in 2022, other income increasing 66.2% to RMB34.2 million, and a shift to positive equity of RMB702.8 million from a RMB470.5 million deficit in 2022 after preferred shares conversion.
Dec-20Series B-$60M-HighTide Therapeutics is a global clinical-stage biopharmaceutical company focused on developing novel multifunctional therapies for metabolic and digestive diseases, with its lead candidate HTD1801 targeting conditions like NASH, PSC, and type 2 diabetes mellitus. HighTide has not yet commercialized any products, remaining pre-revenue with a pipeline in clinical development, including FDA Fast Track and Orphan Drug designations for HTD1801 in the US and inclusion in China's National Major New Drug Innovation Program. The company completed a $60 million Series B+ financing round at the end of 2020, as referenced in their January 2023 Series C/C+ announcement. Subsequent to the 2020 round, HighTide raised $107 million in a Series C/C+ round in January 2023 led by TCM Healthcare Fund of Guangdong, with total funding reaching $217 million since its 2011 founding. Recent developments include plans for NDA submission for HTD1801 in T2DM by end-2025 in China and NMPA acceptance noted in 2026.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About HighTide Therapeutics

When was HighTide Therapeutics founded?HighTide Therapeutics was founded in 2018.
Where is HighTide Therapeutics headquartered?HighTide Therapeutics is headquartered in China.
How many employees does HighTide Therapeutics have?As of today, HighTide Therapeutics has over 70 employees.
Is HighTide Therapeutics publicly listed?Yes, HighTide Therapeutics is a public company listed on HKEX.
What is the stock symbol of HighTide Therapeutics?HighTide Therapeutics trades under 02511 ticker.
When did HighTide Therapeutics go public?HighTide Therapeutics went public in 2023.
Who are competitors of HighTide Therapeutics?HighTide Therapeutics main competitors include
What is the current market cap of HighTide Therapeutics?HighTide Therapeutics' current market cap is $228M.
Is HighTide Therapeutics profitable?No, HighTide Therapeutics is not profitable.
How many companies HighTide Therapeutics has acquired to date?HighTide Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies HighTide Therapeutics has invested to date?HighTide Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

Lists including HighTide Therapeutics

Largest Companies in China

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial